Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GST-HG141 in treated low-viremia chronic hepatitis B (Phase II)
CTR20222978Phase 2Completed
- Sponsor
- Fujian Guansheng Tang Pharmaceutical
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of narecovir in Chronic Hepatitis B (CHB), sponsored by Fujian Guansheng Tang Pharmaceutical. Started Nov 2022; status: completed.
02
Drugs
narecovir
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on CTR20222978.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20222978.